Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ), often known as Sobi, navigates the intricate world of biopharmaceuticals with a singular focus on developing and delivering innovative treatments for rare diseases. Founded in the heart of Scandinavia, Sobi has crafted a unique niche by addressing medical needs that are often overlooked by larger pharmaceutical companies. The company specializes in hematology and immunology, focusing on conditions where it can leverage its expertise to make a tangible difference. With a robust pipeline of biopharmaceutical products, Sobi dedicates itself to research and partnerships that not only drive scientific advancements but also ensure that its therapies reach the global market. This mission aligns with its deep commitment to patients whose conditions lack effective treatments.
Sobi’s business model thrives on a blend of strategic acquisitions, rigorous clinical development, and expansive distribution capabilities. By acquiring promising therapies and collaborating with other innovators in the biotech space, it continually expands its product portfolio and market reach. Revenue flows primarily from the sales of these specialized therapies, which command premium pricing due to their targeted nature and the complex manufacturing processes involved. The company also invests significantly in its research and development programs, channeling insights from its interactions with healthcare professionals and patients to optimize its offerings. Through its relentless focus on rare diseases, Sobi not only secures financial returns but also significantly impacts the quality of life for patients, staying true to its foundational ethos.
Swedish Orphan Biovitrum AB (publ), often known as Sobi, navigates the intricate world of biopharmaceuticals with a singular focus on developing and delivering innovative treatments for rare diseases. Founded in the heart of Scandinavia, Sobi has crafted a unique niche by addressing medical needs that are often overlooked by larger pharmaceutical companies. The company specializes in hematology and immunology, focusing on conditions where it can leverage its expertise to make a tangible difference. With a robust pipeline of biopharmaceutical products, Sobi dedicates itself to research and partnerships that not only drive scientific advancements but also ensure that its therapies reach the global market. This mission aligns with its deep commitment to patients whose conditions lack effective treatments.
Sobi’s business model thrives on a blend of strategic acquisitions, rigorous clinical development, and expansive distribution capabilities. By acquiring promising therapies and collaborating with other innovators in the biotech space, it continually expands its product portfolio and market reach. Revenue flows primarily from the sales of these specialized therapies, which command premium pricing due to their targeted nature and the complex manufacturing processes involved. The company also invests significantly in its research and development programs, channeling insights from its interactions with healthcare professionals and patients to optimize its offerings. Through its relentless focus on rare diseases, Sobi not only secures financial returns but also significantly impacts the quality of life for patients, staying true to its foundational ethos.
Revenue Growth: Sobi delivered 16% revenue growth in Q4 2025 at constant currency, with full-year revenue up 15%, exceeding updated guidance from Q3.
Strategic Portfolio: The strategic portfolio drove performance, now accounting for 65% of Q4 revenues and growing 37% in the quarter.
Profitability: Adjusted EBITDA margin reached 41% in Q4 and 40% for the full year, supported by product mix and operational improvements.
Major Launches & Approvals: Key launches and approvals included Altuvoct in hemophilia A, Aspaveli in nephrology (EU approval), and Tryngolza in Germany.
Pipeline Progress: Positive clinical milestones were achieved across assets including Gamifant in sepsis and Tryngolza in severe hypertriglyceridemia.
2026 Guidance: For 2026, Sobi expects low double-digit revenue growth and an adjusted EBITDA margin in the mid-30s, lower than 2025 due to stepped-up investments in new launches and R&D.
Arthrosi Acquisition: Sobi is set to acquire Arthrosi, adding a late-stage gout asset and expected to increase net debt by about SEK 9 billion.
Beyfortus Outlook: Management expects flat to modest growth for Beyfortus royalties in 2026, with no major headwinds anticipated.
